Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II)

[1]  Aubrey E. Jones,et al.  Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation , 2019, Pharmacy practice.

[2]  R. Arbel,et al.  Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation. , 2019, The American journal of medicine.

[3]  Y. Okumura,et al.  Clinical Outcomes of Off-Label Dosing of Direct Oral Anticoagulant Therapy Among Japanese Patients With Atrial Fibrillation Identified From the SAKURA AF Registry. , 2019, Circulation journal : official journal of the Japanese Circulation Society.

[4]  Gregory Y H Lip,et al.  Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. , 2017, Annals of translational medicine.

[5]  Xiaoxi Yao,et al.  Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. , 2017, Journal of the American College of Cardiology.

[6]  D. Singer,et al.  Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. , 2016, Journal of the American College of Cardiology.

[7]  A. Camm,et al.  XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation , 2015, European heart journal.

[8]  M. Lamberts,et al.  Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. , 2014, Journal of the American College of Cardiology.

[9]  G. Fonarow,et al.  Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. , 2014, American heart journal.